Sebastian Duda / Shutterstock.com
12 September 2016Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
23 May 2018 Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).
Europe
30 March 2021 Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
Editor's picks
Editor's picks
Americas
23 May 2018 Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).
Europe
30 March 2021 Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
Americas
23 May 2018 Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).
Europe
30 March 2021 Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.